The latest price target for Autolus Therapeutics (NASDAQ:AUTL) was reported by Goldman Sachs on November 18, 2024. The analyst firm set a price target for $7.60 expecting AUTL to rise to within 12 months (a possible 167.61% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Autolus Therapeutics (NASDAQ:AUTL) was provided by Goldman Sachs, and Autolus Therapeutics upgraded their buy rating.

The last upgrade for Autolus Therapeutics PLC happened on November 18, 2024 when Goldman Sachs raised their price target to $7.6. Goldman Sachs previously had a neutral for Autolus Therapeutics PLC.

There is no last downgrade for Autolus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Autolus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Autolus Therapeutics was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Autolus Therapeutics (AUTL) rating was a upgraded with a price target of $7.00 to $7.60. The current price Autolus Therapeutics (AUTL) is trading at is $2.84, which is out of the analyst’s predicted range.